It was an absolute pleasure to discuss the 24-week results from the SKIPPAIN study (NCT03136861) with Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany ). The study, which is a phase IIIb trial, evaluated the efficacy and safety of secukinumab in reducing spinal pain and disease activity following a step-up dosing approach.
His presentation entitled ‘Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial’ (ABSTRACT NUMBER: 0899) was presented at ACR Convergence 2020, 5-9 November.
Disclosures: Denis Poddubnyy reports grants and personal fees from AbbVie, personal fees from Bristol-Myers Squibb, grants and personal fees from Eli Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, personal fees from Biocad, personal fees from GlaxoSmithKline and personal fees from Gilead.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. ‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!